Observational studyMedicine2020
T2-weighted cardiac magnetic resonance image and myocardial biomarker in hypertrophic cardiomyopathy.
Observational study in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 9 citations in OpenAlex.
- Novel Magnetic Resonance Imaging Tools for Hypertrophic Cardiomyopathy Risk Stratification.Life (Basel, Switzerland) · 2024Review
- Sarcoid heart disease and imaging.Heart rhythm O2 · 2024Review
- Cardiac Multimodality Imaging in Hypertrophic Cardiomyopathy: What to Look for and When to Image.Current cardiology reviews · 2023Review
- Left ventricular strain patterns and their relationships with cardiac biomarkers in hypertrophic cardiomyopathy patients with preserved left ventricular ejection fraction.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The phenomenon of high signal intensity on T2-weighted imaging of cardiac magnetic resonance in hypertrophic cardiomyopathy (HCM) has been previously studied. However, the underlying histopathologic mechanism remains unclear. Elevated cardiac troponin can be detected in some HCM patients. A reasonable hypothesis is that high myocardial T2 signal is a potential marker of myocardial injury in HCM. We sought to investigate the association between cardiac troponin and the extent of high T2 signals in HCM patients.Forty-four HCM patients underwent 3.0T cardiac magnetic resonance scanning. On T2-weighted images, the number of segments with high-signal intensity (myocardium-to-skeletal muscle signal intensity ratio >2) and the percentage of high-signal area (>2 standard deviation above the remote tissue) were measured in 16 myocardial segments along the LV mid-myocardial circumference on 3 short-axis images. The level of high-sensitivity cardiac troponin T (hs-cTnT) was also assessed.Myocardial high T2 signals were identified in 33 (75%) patients and 144 (20.5%) segments. Elevated hs-cTnT was observed in 28 (63.6%) patients. The Cochran-Armitage test showed a statistically significant trend of increasing levels of hs-cTnT with elevated number of segments with myocardial high T2 signal (P = .002). Further, the percentage of myocardium with high T2 signal was significantly associated with the hs-cTnT level (Pearson correlation: r = 0.388, P = .009).Myocardium with high T2 signals was very common in patients with HCM.Its extent is related with the level of plasma hs-cTnT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.